Results 351 to 360 of about 3,443,356 (396)
Some of the next articles are maybe not open access.
Cancer Letters, 2022
Small cell lung cancer (SCLC) is a highly malignant tumor with extremely poor prognosis. The treatment strategy is very limited, and patient outcomes remain dismal with the 5-year survival rate being mere 3-6%. Thus, novel therapeutic strategies for SCLC
Nannan Zhang +12 more
semanticscholar +1 more source
Small cell lung cancer (SCLC) is a highly malignant tumor with extremely poor prognosis. The treatment strategy is very limited, and patient outcomes remain dismal with the 5-year survival rate being mere 3-6%. Thus, novel therapeutic strategies for SCLC
Nannan Zhang +12 more
semanticscholar +1 more source
Current Breast Cancer Reports, 2011
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCA-deficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF-01367338, and MK-4827.
Hongyan Liang, Antoinette R. Tan
openaire +2 more sources
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCA-deficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF-01367338, and MK-4827.
Hongyan Liang, Antoinette R. Tan
openaire +2 more sources
Expanding biomarkers for PARP inhibitors
Nature Cancer, 2022International audience ; The efficacy of talazoparib and other PARP inhibitors has been primarily reported in germline BRCA mutation carriers. New results establish germline mutations in PALB2, but not in other homologous recombination (HR) genes, as targets for PARP inhibitors in breast cancer, whereas the added predictive value of HR signatures ...
Florence Coussy, Francois-Clement Bidard
openaire +3 more sources
PARP inhibitor combination therapy
Critical Reviews in Oncology/Hematology, 2016In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality.
Christopher J Lord, Alan Ashworth
exaly +4 more sources
The Vasoactivity of PARP Inhibitors
2015PARP-inhibition has proven to be an attractive therapeutic approach in cancer whereby the effectiveness of DNA-damaging therapy can be enhanced by inhibiting the PARP-mediated DNA-repair process. Generally there is good concordance between enhanced therapeutic efficacy in vitro and that observed in vivo.
Williams, Kaye J., McCrudden, Cian M.
openaire +2 more sources
Development of PARP inhibitors in oncology
Expert Opinion on Investigational Drugs, 2008Poly (ADP-ribose) polymerase (PARP) plays a key role in DNA repair mechanisms by detecting and initiating repair after DNA strand breaks. Inhibition of PARP in DNA repair-defective tumors (like those with BRCA1 or BRCA2 mutations) can lead to gross genomic instability and cell death.
Jordi, Rodon +2 more
openaire +2 more sources
Mechanisms of PARP Inhibitor Resistance
2023Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) represent the first medicines based on the targeting of the DNA damage response (DDR). PARPi have become standard of care for first-line maintenance treatment in ovarian cancer and have also been approved in other cancer indications including breast, pancreatic and prostate.
Mark J, O'Connor, Josep V, Forment
openaire +2 more sources
Adverse events of PARP inhibitors
Česká gynekologie, 2021An evaluation of the safety of poly-ADP-ribose-polymerase inhibitors (PARPi) in ovarian cancer treatment.An analysis of the studies on PARP inhibitors, a summary of the most common and serious adverse events.According to the studies, the most common adverse events of PARPi include hematotoxicity, nausea and vomiting.
Martina, Romanová, Jaroslav, Klát
openaire +2 more sources
Nature Reviews Clinical Oncology, 2020
The much anticipated results from two phase III studies evaluating the clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibition in patients with advanced-stage breast cancer harbouring a germline mutation in BRCA1/2 have established new therapeutic opportunities and yet, have left us with several ongoing questions.
Shani Paluch-Shimon, Fatima Cardoso
openaire +2 more sources
The much anticipated results from two phase III studies evaluating the clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibition in patients with advanced-stage breast cancer harbouring a germline mutation in BRCA1/2 have established new therapeutic opportunities and yet, have left us with several ongoing questions.
Shani Paluch-Shimon, Fatima Cardoso
openaire +2 more sources
PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes
Expert Review of Anticancer TherapyPoly(ADP-ribose) polymerase 1 (PARP1) inhibition has become a major target in anticancer therapy. While PARP inhibitors (PARPi) are approved for homologous recombination (HR) deficient cancers, therapeutic resistance is a challenge and PARPi are now being investigated in cancers lacking HR deficiencies.
Tony, Yu, Benjamin H, Lok
openaire +2 more sources